145 related articles for article (PubMed ID: 37389896)
21. Preoperative serum CA19-9 predicts postoperative pancreatic fistula in PDAC patients: retrospective analysis at a single institution.
Sugita H; Okabe H; Ogawa D; Hirao H; Kuroda D; Taki K; Tomiyasu S; Hirota M
BMC Surg; 2022 Oct; 22(1):367. PubMed ID: 36307795
[TBL] [Abstract][Full Text] [Related]
22. New Cancer-Related Symptoms Predict Recurrence in CA19-9 Non-Expressers After Resection of Pancreatic Ductal Adenocarcinoma.
Amburn T; Davenport D; Patel R; Moss J; Pandalai P; Kim J; Cavnar M
Am Surg; 2023 Nov; 89(11):4469-4478. PubMed ID: 35921431
[TBL] [Abstract][Full Text] [Related]
23. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
Li D; Peng Q; Wang L; Cai W; Liang M; Liu S; Ma X; Zhao X
Eur Radiol; 2024 Jan; 34(1):509-524. PubMed ID: 37507611
[TBL] [Abstract][Full Text] [Related]
24. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19-9 Reference Ranges.
Dbouk M; Abe T; Koi C; Ando Y; Saba H; Abou Diwan E; MacGregor-Das A; Blackford AL; Mocci E; Beierl K; Dbouk A; He J; Burkhart R; Lennon AM; Sokoll L; Canto MI; Eshleman JR; Goggins M
Clin Cancer Res; 2023 Oct; 29(20):4178-4185. PubMed ID: 37566230
[TBL] [Abstract][Full Text] [Related]
26. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
27. The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.
Staal B; Liu Y; Barnett D; Hsueh P; He Z; Gao C; Partyka K; Hurd MW; Singhi AD; Drake RR; Huang Y; Maitra A; Brand RE; Haab BB
Clin Cancer Res; 2019 May; 25(9):2745-2754. PubMed ID: 30617132
[TBL] [Abstract][Full Text] [Related]
28. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
29. Accuracy of simultaneous measurement of serum biomarkers: Carbohydrate antigen 19-9, pancreatic elastase-1, amylase, and lipase for diagnosing pancreatic ductal adenocarcinoma.
Yang CY; Lin RT; Chen CY; Yeh CC; Tseng CM; Huang WH; Lee TY; Chu CS; Lin JT
J Formos Med Assoc; 2022 Dec; 121(12):2601-2607. PubMed ID: 35918272
[TBL] [Abstract][Full Text] [Related]
30. Postoperative Carbohydrate Antigen 19-9 Level as a Good Indicator of Ineffective Response to the Currently Recommended S-1 Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma: A Single-Center, Retrospective Study.
Ariake K; Okada T; Tsuchiya H; Kuboki D; Maemura K; Okada Y; Ichikawa H; Tachibana T; Akazawa N; Abe T; Kakita T; Oikawa M; Tsuchiya T
Ann Surg Oncol; 2024 Jan; 31(1):525-534. PubMed ID: 37851194
[TBL] [Abstract][Full Text] [Related]
31. Biological risk based on preoperative serum CA19-9 and histological grade predicts prognosis and improves accuracy of classification in patients with pancreatic ductal adenocarcinoma.
Chang S; Liu Y; Liang Y; Man Q; Li H; Guo Y; Zhao T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1911. PubMed ID: 37827990
[TBL] [Abstract][Full Text] [Related]
32. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
33. Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer.
Takagi C; Kikuchi Y; Shirakawa H; Hoshimoto S; Tomikawa M; Ozawa I; Hishinuma S; Ogata Y
Anticancer Res; 2019 Jun; 39(6):3177-3183. PubMed ID: 31177164
[TBL] [Abstract][Full Text] [Related]
34. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
[TBL] [Abstract][Full Text] [Related]
35. Preoperative carbohydrate antigen 19-9 and standard uptake value of positron emission tomography-computed tomography as prognostic markers in patients with pancreatic ductal adenocarcinoma.
Moon D; Kim H; Han Y; Byun Y; Choi Y; Kang J; Kwon W; Jang JY
J Hepatobiliary Pancreat Sci; 2022 Oct; 29(10):1133-1141. PubMed ID: 33063453
[TBL] [Abstract][Full Text] [Related]
36. Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients.
Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
Sci Rep; 2021 Oct; 11(1):20797. PubMed ID: 34675229
[TBL] [Abstract][Full Text] [Related]
37. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
[TBL] [Abstract][Full Text] [Related]
38. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
39. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
[TBL] [Abstract][Full Text] [Related]
40. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preoperative chemoradiotherapy.
Murata Y; Ogura T; Hayasaki A; Gyoten K; Ito T; Iizawa Y; Fujii T; Tanemura A; Kuriyama N; Kishiwada M; Sakurai H; Mizuno S
PLoS One; 2022; 17(4):e0264573. PubMed ID: 35377885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
